section name header

Indications

High Alert


Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

Interactions

Drug-drug:

Availability

Route/Dosage

US Brand Names

Zydelig

Action

  • Acts as an inhibitor of phosphatidylinositol 3-kinase; induces apoptosis and inhibits cell proliferation in malignant B-cell and tumor cells; also inhibits some cell-signaling pathways, chemotaxis, adhesion, and cell viability.
Therapeutic effects:
  • Decreased progression of CLL.

Classifications

Therapeutic Classification: antineoplastics

Pharmacologic Classification: kinase inhibitors

Pharmacokinetics

Absorption: Well absorbed following oral administration.

Distribution: Unknown.

Metabolism/Excretion: Primarily metabolized by the liver via the CYP3A isoenzymes. Metabolites are excreted in feces (78%) and urine (14%).

Half-Life: 8.2 hr.

Time/Action Profile

( in progression-free survival)
ROUTEONSETPEAKDURATION
PO2 mo6 mo10–12 mo

Noted for CLL.



Patient/Family Teaching

Pronunciation

EYE-dela-li-sib